Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2000

View Archived Issues

Ixion receives SBIR grant for oxalate degradation research

Acadia identifies novel mechanism of action for antipsychotics

FDA approves Androgel for treatment of hypogonadism

Myogen and UT Southwestern Medical Center collaborate on heart failure treatment

Elan's NDA for ziconotide accepted for filing

C5 inhibitor from Alexion granted fast track status for kidney disease

Human Genome Sciences and CAT to collaborate on antibody development program

Hepatitis C vaccine candidate identified by Epimmune

VEGF-targeted antisense oligonucleotides inhibit tumor growth

Effects of homocysteine lowering with vitamins on subclinical atherosclerosis

New macrolide antibiotics effective against Gram-positive microorganisms

Nonimmunosuppressive immunophilin-binding neurotrophic compounds designed at Pfizer

U.K.'s MCA approves another new meningitis C vaccine

EGF-genistein: a new pharmacological approach to treating, preventing restenosis

SB discloses production and use of Scrp-5 polypeptides/polynucleotides

Aptosyn/Gemzar cancer trials to begin shortly

Steroidogenesis Inhibitors seeks South African partner to assist in development of AIDS drug

Antitumor immunity induced by elemene involves enhancement of HSP70 expression

Successful clinical results with IDEA's drug delivery system trigger payment from P&G

Feasibility of HSV-TK/GCV gene therapy demonstrated in glioblastoma multiforme

FDA puts VEGF-2 trials on hold

Pharmacyclics initiates phase I clinical trial of Antrin for treatment of coronary artery disease

ISIS-14803 begins phase I/II evaluation as HCV treatment

Potential role for perillyl alcohol in cardiovascular disease

Alocril now available in U.S. for itch associated with allergic conjunctivitis

Several new approvals obtained for Gliadel

Maxygen enters CRADA with NCI for anticancer proteins

Biopure's oxygen therapeutic restores brain oxygenation after hemorrhagic shock

Neutralase effectively reverses new anticoagulants

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...